This fresh capital will allow the French biotech – which was founded in 2009 and which specializes in the development of gene therapies to restore hearing in people with congenital deafness – to continue its pioneering work. The company, which has been listed on Euronext since 2015, is bringing in the French pharmaceutical group Sanofi as a new shareholder. After investing €20 million, Sanofi will hold 13.9% of Sensorion's capital. While Sanofi's investment is modest compared to its overall revenue (€41.1 billion in 2024), its arrival gives the young company greater visibility. At market close on Wednesday, shares in the biotech – which have been slumping for a year – jumped 22%, pushing its valuation above €100 million.